<ѻýҕl>Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytesѻýҕl> Almost a third of patients had objective responses, which deepened over time, study showed Nov 16, 2022
<ѻýҕl>Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Responseѻýҕl> Encouraging activity with antibiotic-free protocol but not with vancomycin preconditioning Nov 14, 2022
<ѻýҕl>Terry Bradshaw's Merkel Cell Carcinomaѻýҕl> After beating bladder cancer, the Hall of Fame quarterback was diagnosed with a rare skin tumor Nov 10, 2022
<ѻýҕl>Immunotherapy First for BRAF Melanoma Edges Out Targeted Combinationѻýҕl> "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
<ѻýҕl>Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanomaѻýҕl> Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
<ѻýҕl>Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinomaѻýҕl> Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
<ѻýҕl>Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Optionѻýҕl> More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
<ѻýҕl>Keytruda Plus T-VEC Falls Short in Unresectable Melanomaѻýҕl> No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
<ѻýҕl>Are Skin Lesion Analyzers Ready for Prime Time?ѻýҕl> FDA panel not fully on board to reclassify computer-aided melanoma detection devices Jul 30, 2022
<ѻýҕl>TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progressionѻýҕl> More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
<ѻýҕl>Something Fishy About Tuna and Melanoma Riskѻýҕl> Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
<ѻýҕl>Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparencyѻýҕl> News, features, and commentary about cancer-related issues Apr 22, 2022
<ѻýҕl>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1ѻýҕl> But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<ѻýҕl>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1ѻýҕl> Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<ѻýҕl>Novel Fixed-Dose Immunotherapy Combo Wins FDA Approvalѻýҕl> Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
<ѻýҕl>Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancerѻýҕl> Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
<ѻýҕl>Novel Therapies Active in Head and Neck Cancersѻýҕl> High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
<ѻýҕl>Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancersѻýҕl> 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
<ѻýҕl>Active Surveillance for Melanoma Meets Reality of Loss to Follow-Upѻýҕl> More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
<ѻýҕl>Melanoma Patient on Immunotherapy Develops Severe Dermatitisѻýҕl> Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
<ѻýҕl>Long-Term Data Reinforce Standard of Care in Unresectable Melanomaѻýҕl> Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
<ѻýҕl>Case: VEGFR Inhibition in Merkel Cell Carcinoma Patientѻýҕl> Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
<ѻýҕl>FDA Issues Orders Clarifying Rules for Marketing Sunscreensѻýҕl> But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
<ѻýҕl>In RA, Little Risk for Recurrent Cancer With Biologic Treatmentѻýҕl> Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
<ѻýҕl>Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanomaѻýҕl> Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
<ѻýҕl>9/11 Responders Face Higher Risk of Multiple Cancersѻýҕl> Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
<ѻýҕl>What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor?ѻýҕl> Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
<ѻýҕl>COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxedѻýҕl> A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
<ѻýҕl>Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survivalѻýҕl> News, features, and commentary about cancer-related issues Jun 16, 2021
<ѻýҕl>Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanomaѻýҕl> But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
<ѻýҕl>Lymph Node Findings on PET: Cancer or COVID Vaccine?ѻýҕl> Post-jab radiotracer uptake "could prompt unnecessary biopsies and treatments" May 26, 2021
<ѻýҕl>Bad Day Sunshine: Benzene Found in Many Sun Care Productsѻýҕl> Valisure also detected the carcinogen in hand sanitizers earlier this year May 26, 2021
<ѻýҕl>Novel Immunotherapy Boosts Melanoma Outcomesѻýҕl> Adding LAG-3 checkpoint inhibitor to nivolumab extended PFS in patients with advanced disease May 19, 2021
<ѻýҕl>Doubling Down on Immunotherapy in Advanced Melanomaѻýҕl> Checkpoint inhibitor combo active after upfront anti-PD-1/L1 therapy May 09, 2021
<ѻýҕl>Op-Ed: Dermatology Needs Lower Costs and Better Careѻýҕl> A proposal for value-based care Apr 21, 2021
<ѻýҕl>Nivolumab Alone Prevails in Resected Melanomaѻýҕl> Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
<ѻýҕl>A Win for Adjuvant Immunotherapy in Esophageal Cancerѻýҕl> And other highlights from the Society of Surgical Oncology's virtual 2021 meeting Mar 31, 2021
<ѻýҕl>Want Data on Recently Approved Actinic Keratosis Drug? Here You Goѻýҕl> Phase III trial now published in full for topical anti-proliferative treatment Feb 10, 2021
<ѻýҕl>First Immunotherapy Approved for Basal Cell Carcinomaѻýҕl> Objective responses in 27% of previously treated patients who received cemiplimab Feb 10, 2021
<ѻýҕl>IL-8 Antibody Active in Tumors After PD-1/L1 Blockadeѻýҕl> Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo Nov 13, 2020